Please use this identifier to cite or link to this item:
doi:10.22028/D291-35470
Title: | Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity |
Author(s): | Koch, Elias A. T. Petzold, Anne Wessely, Anja Dippel, Edgar Gesierich, Anja Gutzmer, Ralf Hassel, Jessica C. Haferkamp, Sebastian Kähler, Katharina C. Knorr, Harald Kreuzberg, Nicole Leiter, Ulrike Loquai, Carmen Meier, Friedegund Meissner, Markus Mohr, Peter Pföhler, Claudia Rahimi, Farnaz Schadendorf, Dirk Schell, Beatrice Schlaak, Max Terheyden, Patrick Thoms, Kai-Martin Schuler-Thurner, Beatrice Ugurel, Selma Ulrich, Jens Utikal, Jochen Weichenthal, Michael Ziller, Fabian Berking, Carola Heppt, Markus V. |
Language: | English |
Title: | Cancers |
Volume: | 14 |
Issue: | 3 |
Publisher/Platform: | MDPI |
Year of Publication: | 2022 |
Free key words: | uveal melanoma immune checkpoint blockade PD-1 CTLA-4 re-induction treatment resistance toxicity |
DDC notations: | 610 Medicine and health |
Publikation type: | Journal Article |
Abstract: | Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1–23.8) versus 9.4 months (cohort B, 95% CI: 6.1–14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities. |
DOI of the first publication: | 10.3390/cancers14030518 |
Link to this record: | urn:nbn:de:bsz:291--ds-354700 hdl:20.500.11880/32402 http://dx.doi.org/10.22028/D291-35470 |
ISSN: | 2072-6694 |
Date of registration: | 17-Feb-2022 |
Faculty: | M - Medizinische Fakultät |
Department: | M - Dermatologie |
Professorship: | M - Keiner Professur zugeordnet |
Collections: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Files for this record:
File | Description | Size | Format | |
---|---|---|---|---|
cancers-14-00518-v2.pdf | 712,15 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License